Contact Information
  • 800-826-HOPE (4673)
Clarke Anderson, M.D.
  • Assistant Clinical Professor
  • Staff Physician, Pediatrics

Primary Specialties

Departments/Division/Program

Professional Experience

  • 2005 - present, Physician, Department of Pediatrics, City of Hope, Duarte, CA
  • 2006 - present, Board Director, Desi Geestman Foundation
  • 2003 - 2005, Director, Cancer Survivorship Clinic, Childrens Hospital Los Angeles, Los Angeles, CA
  • 2002 - present, Founding Member, Children’s Hospice and Care
  • 1997 - 2005, Assistant Professor of Pediatrics, Childrens Hospital Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, CA
  • 1996 - 1997, Instructor of Pediatrics, Childrens Hospital Los Angeles, University of Southern California, Keck School of Medicine

Education

Education/Training
  • 1992 - 1996, Childrens Hospital Los Angeles, Division of Pediatric Hematology/Oncology, Fellow
  • 1991 - 1992, Creighton University/University of Nebraska, Combined Pediatric Residency Program, Resident and Chief Resident
  • 1990 - 1991, Creighton University, Department of Pediatrics, Resident
  • 1989 - 1990, Creighton University, Department of Pediatrics, Internship
  • 1985 - 1989, Creighton University School of Medicine, Omaha, NE, M.D
  • 1979 - 1983, Creighton University, Omaha, NE, B.S.M.T

Board Certifications/Licensure
  • 2003, American Board of Hospice and Palliative Medicine
  • 1998, American Board of Pediatric Hematology/Oncology
  • 1992, American Board of Pediatrics, Re-certified, 1999
  • 1992, State of California

Honors/Awards

Awards
  • 2003, Best Abstract Award, European Association Palliative Care, 8th Congress, Den Hague, Netherlands
  • 2001, Barbara Korsch Award for Excellence in Medical Education

Honors
  • 2004, Carsen Russell Crouch Memorial Lectureship, CHLA
  • 2002, These Three Words, Honoree for Pediatric Palliative Care

Publications

  • Anderson CP, Tsai JM, Chan WW, Park CK, Liu RM, Forman HJ, Reynolds CP: Buthionine sulfoximine is cytotoxic via apoptosis and synergistically enhances the activity of melphalan in human neuroblastoma cell lines. Proceedings of 32th Annual Meeting , Amer. Soc. Clin. Oncol, 1996. (abstract).
  • Anderson CP, Tsai JM, Chan WW, Park CK, Liu RM, Forman HJ, Reynolds CP: Buthionine sulfoximine is cytotoxic and enhances the activity of melphalan for human neuroblastoma cell lines. Advances in Neuroblastoma Research 1996, Philadelphia, PA. (oral presentation of abstract).
  • Anderson CP, Nandy P, Periclou A, Avramis VI: Pharmacodynamic (PD) modeling studies of cytarabine (ara-c) in pediatric leukemia patients. Medical and Pediatric Oncology, 29(5):336, 1997. (oral presentation of abstract).
  • Anderson CP, Seeger RC, Matthay KK, et al.: A phase I trial of buthionine sulfoximine in combination with melphalan for children with recurrent neuroblastoma. Advances in Neuroblastoma Research 1998, Bath, UK (oral presentation of abstract).
  • Anderson CP, Seeger RC, Matthay KK, et al.: A phase I trial of buthionine sulfoximine in combination with melphalan for children with recurrent neuroblastoma. Advances in Neuroblastoma Research 1998, Bath, UK (oral presentation of abstract).
  • Anderson CP, Seeger RC, Matthay KK, Neglia JP, Bailey HH, Reynolds CP: Pilot study of buthionine sulfoximine and melphalan in children with recurrent neuroblastoma. Proceedings of 34th Annual Meeting , Amer. Soc. Clin. Oncol 17: 531a, 1998. (abstract).
  • Anderson CP, Castro CS, Meeks WM, Satake N, Reynolds CP: Physiologic bone marrow oxygen tension (O2T) contributes to buthionine sulfoximine (BSO) resistance in neuroblastoma. Medical and Pediatric Oncology, 33(3):266, 1999. (abstract).
  • Anderson CP, Seeger RC, Matthay KK, et al.: Buthionine sulfoximine alone and in combination with melphalan is active against recurrent neuroblastoma. Medical and Pediatric Oncology, 33(3):158, 1999. (oral presentation of abstract).
  • Anderson CP, Keshelava N, Meeks WH, Satake N, Reynolds CP: Buthionine sulfoximine (BSO) synergizes the action of melphalan (L-PAM) for neuroblastoma cell lines established after disease progression in intensively treated patients. Advances in Neuroblastoma Research 2000, Philadelphia, PA. (oral presentation of abstract).
  • Anderson CP, Castro CS, Meeks WM, Satake N, Reynolds CP: Physiologic bone marrow oxygen tension (O2T) contributes to buthionine sulfoximine (BSO) resistance in neuroblastoma. General Clinical Research Center National Meeting, Washington, D.C., March 2001.
  • Anderson CP, Seeger RC, Matthay KK, Neglia JP, Bailey HH, Reynolds CP: Pilot study of buthionine sulfoximine and melphalan in children with recurrent neuroblastoma. Proceedings of 38th Annual Meeting, Amer. Soc. Clin. Oncol 21:398a, 2002.
  • Anderson CP, Seeger RC, Matthay KK, Neglia JP, Bailey HH, Reynolds CP: Pilot study of buthionine sulfoximine and melphalan in children with recurrent neuroblastoma. Advances in Neuroblastoma Research 2002, Paris, France.
  • Bo.Yang, Nino Kelshelava, Clarke P. Anderson and C. Patrick Reynolds Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia is Reversed by the Bioreductive Agent Tirapazamine Advances in Neuroblastoma Research 2002, Paris, France.
  • M.E. Estany, K. McGinty, and Anderson CP. The use of Reiki as a complementary therapy for pediatric palliative care, 8th European Association Palliative Care, Den Hague, 2003.
  • Lambrecht T and Anderson CP. Multidisciplinary Survey of Pediatric Palliative Care: Attitudes and Experience in a Large Metropolitan Pediatric Hospital. 8th European Association Palliative Care, Den Hague, 2003 (received award for best abstract).
  • Lambrecht T and Anderson CP. Multidisciplinary attitudes toward cultural and spiritual beliefs In pediatric palliative care. 8th European Association Palliative Care, Den Hague, 2003.

Locations

City of Hope - Main Campus
1500 East Duarte Road
Duarte, CA 91010
 
City of Hope - Antelope Valley
44151 15th St. West
Lancaster, CA 93534
 
City of Hope - South Pasadena
209 S. Fair Oaks Ave.
So. Pasadena, CA 91030